Kyntra Bio Inc. (KYNB) Stock Price

6.93 ▼ -0.04 (-0.57%)
Open: 6.98 Vol: 43.76K Day's range: 6.82 - 7.0644 Feb 27, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
KYNB Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 6.92▲ 6.92▲ 6.91▲ 7.30▼ 7.76▼
MA10 6.94▼ 7.02▼ 7.05▼ 7.52▼ N/A    
MA20 7.15▼ 7.41▼ 7.55▼ 7.71▼ N/A    
MA50 7.77▼ 7.67▼ 7.68▼ N/A     N/A    
MA100 7.76▼ 7.88▼ 8.01▼ N/A     N/A    
MA200 8.11▼ N/A     N/A     N/A     N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD 0.010▲ -0.045▼ -0.065▼ N/A     N/A    
RSI 34.481▼ 35.681▼ 34.830▼ 35.875▼ N/A    
STOCH 38.194     22.380     17.807▼ 22.354     N/A    
WILL %R -66.667     -79.012▼ -84.404▼ -94.931▼ N/A    
CCI -43.726     -69.809     -79.088     -145.486▼ N/A    
Latest Filters Detected On KYNB
▼ BREAK $KYNB Price Breaks 30 Days Low Set Alert
▼ BREAK $KYNB Price Breaks 20 Days Low Set Alert
▼ BREAK $KYNB Price Breaks 10 Days Low Set Alert
CDL $KYNB Doji Candlestick Pattern Detected Set Alert
Kyntra Bio Inc. News
What's Going On With Kyntra Bio Stock Tuesday?
Tuesday, February 24, 2026 05:27 AM
Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating ...
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant ...
Monday, February 23, 2026 02:25 PM
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant ...
Monday, February 23, 2026 02:10 PM
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer ...
KYNB historical stock data
date open high low close volume
27/02/26 6.98 7.0644 6.82 6.93 43,764
26/02/26 7.21 7.21 6.95 6.97 69,500
25/02/26 7.51 7.72 7.11 7.27 45,040
24/02/26 7.86 7.96 7.25 7.28 111,547
23/02/26 8.17 8.5837 7.95 8.05 30,979
20/02/26 7.99 8.99 7.99 8.32 51,680
19/02/26 7.71 7.98 7.70 7.84 19,193
18/02/26 7.67 8.00 7.495 7.79 20,600
17/02/26 7.36 7.625 7.15 7.33 44,102
13/02/26 7.50 7.80 7.45 7.45 10,500
Quote Details
52wk Low:6.82
52wk High:9.58
Vol:43.76K
Avg Vol(3m):556.5K
1Y Chng:+0.00%
1M Chng:-23.59%
Add to Watch List
More Information
Index US Composite
Market Cap. 28.20M